Foxo4-DRI

What it is (in plain language)
- It's a biological 'rubbish cleaner'. As we age, we accumulate 'zombie' (senescent) cells that don't die, but emit inflammatory toxins. Foxo4-DRI identifies these cells and forces them to self-destruct, allowing the tissue to regenerate with healthy cells.

Why do you appear online so much
- It's one of the most exciting frontiers in anti-ageing science. It went viral after studies showed that it 'rejuvenated' elderly mice, restoring their fur, kidney function and agility.

How it is framed today (pragmatic view)
- 1) Evidence: Experimental, with impressive laboratory results; human trials are limited. 2) Purpose: Organ rejuvenation and elimination of systemic inflammation (inflammaging). 3) Risk: Potential renal toxicity if doses are excessive; requires monitoring.

How to use this form
- Read about the concept of 'Cellular Senescence' in the attached scientific links.

- Quick profile (curated by Subject 157)
- Class: Other
- Status: Verified
- Use case: Other
- Route: Injectable
- Tags: Injectable|Longevity|Experimental
- Half-life: Unknown
- Start: Slow
- Duration: Variable

- Mechanism (high level)
Interferes with the p53-Foxo4 interaction. Blocks the nuclear transport of Foxo4, freeing p53 to induce apoptosis (cell death) specifically in senescent cells that accumulate damage.

- Evidence (what the literature covers)
RANGE OF RESEARCH (Pre-clinical - Rats, Non-prescriptive):
High doses in animal models. Human use is experimental and risky.
Level of Evidence: C (Seminal studies in rats, no robust human data).

- Safety and harm-reduction (non-prescriptive)
Risks: Unknown risk of systemic toxicity.
Interactions: Unknown.

- References (anchors)
- Baar, M. P. (2017) - Targeted apoptosis of senescent cells by FOXO4 peptide - https://doi.org/10.1016/j.cell.2017.02.031
- PubMed:28340339

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.